The Insight Partners Latest Research on “Epirubicin Market Forecast to 2028″ Includes COVID-19 Impact and Global Analysis By Dosage (10mg/Vial, 50mg/Vial, 100mg/Vial and 200mg/Vial), Application (Breast cancer, Liver Cancer, Bladder Cancer, and Others), and Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies)
“Epirubicin Market was valued at US$ 191.66 million in 2021 and is projected to reach US$ 243.99 million by 2028; it is estimated to grow at a CAGR of 3.60% from 2022 to 2028. Rising prevalence of cancer and increasing awareness about cancer are propelling the market growth. However, the elevated risk of adverse effects due to epirubicin is hampering the market’s growth.
Download PDF Sample Copy at: https://www.theinsightpartners.com/sample/TIPRE00008627/
Epirubicin HCl is a class of drugs termed anthracyclines and is primarily used to treat breast cancers after surgical resection. Anthracyclines are an antibiotic isolated from the gram-positive bacteria Streptomyces. They are commonly used as chemotherapy agents and exert their antineoplastic effects by targeting the replication of DNA. Epirubicin HCl is often preferred over anthracycline doxorubicin as it has been shown to have fewer side effects. Epirubicin HCl became FDA-approved as adjuvant therapy for treating axillary node-positive breast cancers following resection under the trade name Ellence in 1999. It is currently manufactured through large-scale semi-synthetic methods using daunorubicin as starting material for its preparation.
Top Players Analysis:
The epirubicin market majorly consists of the players such as Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Salius Pharma Pvt Ltd; Areva Pharamceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; and Miracalus Pharma Pvt. Ltd. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgradations for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the epirubicin market:
April 2018: Hikma Pharmaceuticals PLC (Hikma, Group) announced that its wholly-owned US subsidiary West-Ward Pharmaceuticals Corp. (West-Ward), had launched Epirubicin Hydrochloride Injection, USP, 50mg/25mL and 200mg/100mL vials, the generic equivalent to Ellence. West-Ward’s Epirubicin Hydrochloride Injection, USP is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Ask for Discount at: https://www.theinsightpartners.com/discount/TIPRE00008627/
According to the American Cancer Society, the global burden of cancer is estimated to have risen to 19,300 new cases in 2021 and 10,000 deaths in 2020. According to stats by the institute, in the US, nearly 18,000 people were diagnosed with cancer, and about 606,520 people developed the disease in 2020. According to the International Agency for Research on Cancer, in 2020, the incidence of breast cancer was 2,261,419, accounting for approximately 11.7% of the total cancer cases globally. Moreover, the disease accounted for 684,996 mortalities in 2020. Thus, the high incidence rate associated with cancer is expected to impact market growth significantly. According to the Centers for Disease Control and Prevention (CDC), each year in the US, ~24,500 men and ~10,000 women get liver cancer, and nearly 18,600 men and 9,000 women die from the disease. The percentage of Americans who get liver cancer has been rising for several decades. Liver cancer is more common in other parts of the world than in the US. Hence, the rising prevalence of cancer cases is driving the epirubicin market.
Based on dosage, the epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial.
Based on application, the market is segmented into breast cancer, liver cancer, bladder cancer, and others.
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
By geography, the epirubicin market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Buy Report at: https://www.theinsightpartners.com/buy/TIPRE00008627/
About The Insight Partners:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi